Astellas (4503) Stock Price, Fundamentals & Analysis

What 4503 does

Astellas (4503) is a stock in the Healthcare sector, specifically in the Drug Manufacturers - General industry, listed on the Tokyo Stock Exchange. The company researches, develops, manufactures, sells, and supplies pharmaceuticals in Japan and internationally. Its portfolio includes treatments for prostate cancer, acute myeloid leukemia, gastric adenocarcinoma, and metastatic urothelial carcinoma, as well as therapies for menopause symptoms, age-related macular degeneration, overactive bladder, and immunosuppression. Astellas is part of the Japanese equity market and is often compared with peers such as Takeda Pharmaceutical (4502), Chugai Pharmaceutical (4519), and Eisai (4523).

Key numbers explained

• Price: 2,399 JPY is the latest trading price of one share.
• Trailing P/E ratio: 14.8 shows the price relative to the last 12 months of earnings; a lower number can suggest the stock is cheaper relative to earnings, but context matters.
• Forward P/E ratio: 31.7 uses expected future earnings, reflecting what investors are paying for growth expectations.
• Dividend yield: 3.33% is the annual dividend as a percentage of the current price, indicating the cash return shareholders receive.
• Ex-dividend date: Sep 29, 2026 is the date by which you must own the stock to receive the next dividend payment.
• Beta: 0.09 suggests the stock’s price tends to move much less than the overall market.
• 52-week range: 1,557.5 – 2,717 shows the lowest and highest prices over the past year.
• Revenue growth: 26.7% year over year indicates how quickly the company’s top line has expanded.

What to watch

Investors tracking Astellas (4503) often watch its upcoming earnings release on Oct 29, 2026, which can move the stock. The 48% share of earnings paid out as dividends highlights the company’s payout policy, while the 30.3% debt-to-equity ratio reflects its use of borrowed capital. Being part of the Nikkei 225 index means it is a large, liquid stock often followed by institutional investors. Broader factors that typically affect this kind of stock include drug approval cycles, patent expirations, currency movements, and healthcare policy changes.